The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib

This publication has 37 references indexed in Scilit:

• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
  European Journal of Cancer, 2012
• EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
  Journal of Hepatology, 2012
• Hepatocellular carcinoma
  The Lancet, 2012
• Management of Hepatocellular Carcinoma: An Update Δσ
  Hepatology, 2011
• Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection
  Alimentary Pharmacology & Therapeutics, 2010
• Future perspectives in hepatocellular carcinoma
  Digestive and Liver Disease, 2010
• Novel inhibitors in development for hepatocellular carcinoma
  Expert Opinion on Investigational Drugs, 2010
• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
  The Lancet Oncology, 2009
• Sorafenib in Advanced Hepatocellular Carcinoma
  New England Journal of Medicine, 2008
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
  Cancer Research, 2004